Vaxart, Inc. VXRT
Nov 4, 2026, 3:59 PM EST
- YTD
- +14.29%
- 1 year
- +21.21%
- Market cap
- 97.48M
- Revenue (ttm)
- 13.93M
- EPS (ttm)
- 0.17
- Shares out
- 227.48M
- P/E ratio
- 2.35
- Forward P/E
- -1.47
- YTD return
- +14.29%
- 1-year return
- +21.21%
- Volume
- 48.72K
- Avg volume
- 280.60K
- Open
- 0.40
- Previous close
- 0.40
- Day's range
- 0.3855 – 0.4095
- 52-week range
- 0.32 – 0.84
- Beta
- 0.70
- Price target
- 4.83 (+1108.3%)
5D -0.0249 (-5.93%)
Key statistics
- Enterprise value
- 103.83M
- PEG ratio
- 0.00
- Price / sales
- 9.82
- Price / book
- 1.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 371.40%
- Free cash flow
- -31.74M
- Total cash
- 62.59M
- Total debt
- 23.13M
- Return on equity
- -91.66%
- Short % of float
- 5.00%
- 50-day average
- 0.6812
- 200-day average
- 0.7986
Analyst view
- Target (low)
- 2.50
- Target (mean)
- 4.83
- Target (high)
- 8.00
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.11.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.10 | -0.06 | +0.04 | +40.00% |
| Aug 8, 2024 | Jun 1, 2024 | 0.03 | -0.09 | -0.12 | -400.00% |
| May 13, 2024 | Mar 1, 2024 | -0.16 | -0.14 | +0.02 | +12.50% |
| Mar 14, 2024 | Dec 1, 2023 | -0.15 | -0.12 | +0.03 | +20.00% |
| Nov 2, 2023 | Sep 1, 2023 | -0.18 | -0.11 | +0.07 | +38.89% |
| Aug 3, 2023 | Jun 1, 2023 | -0.19 | -0.16 | +0.03 | +15.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2024 | Oppenheimer | init | — | Outperform |
| Jan 31, 2024 | B. Riley Securities | up | Neutral | Buy |
| Sep 7, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 7, 2023 | Cantor Fitzgerald | main | Overweight | Overweight |
| Dec 19, 2022 | B. Riley Securities | main | — | Neutral |
| Sep 2, 2022 | Cantor Fitzgerald | main | — | Overweight |
About Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vaxart.com
News
Vaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ET 
Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model 
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference 
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference 
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology 
Vaxart Q2 Earnings Call Highlights 
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript 
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET 
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now 
Vaxart to Participate in BTIG Biotechnology Conference 2026
Your note
Sign in to keep a note on VXRT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERG EDWARD B | General Counsel | Stock Award(Grant) | Mar 17, 2024 | 270,706 |
| CUMMINGS JAMES F. | Officer | Stock Award(Grant) | Mar 17, 2024 | 330,093 |
| FINNEY MICHAEL J | Director | Stock Award(Grant) | Jun 10, 2024 | 686,840 |
| HERON ELAINE J | Director | Stock Award(Grant) | Jun 10, 2024 | 40,566 |
| LEE PHILLIP E. | Chief Financial Officer | Stock Award(Grant) | Mar 17, 2024 | 241,808 |
| LO STEVEN | Chief Executive Officer | Stock Award(Grant) | Mar 17, 2024 | 250,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sio Capital Management, LLC | 5.98% | 13,608,244 | 8.18M | Sep 29, 2024 |
| Vanguard Group Inc | 4.43% | 10,077,418 | 6.06M | Sep 29, 2024 |
| Millennium Management Llc | 1.74% | 3,969,091 | 2.39M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.12% | 2,543,228 | 1.53M | Sep 29, 2024 |
| Blackrock Inc. | 0.78% | 1,774,346 | 1.07M | Sep 29, 2024 |
| SilverArc Capital Management, LLC | 0.44% | 1,000,000 | 601.20K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.15% | 7,158,987 | 4.30M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.11% | 2,523,623 | 1.52M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.53% | 1,203,667 | 723.64K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 385,768 | 231.92K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index ETF | 0.14% | 323,489 | 194.48K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 284,335 | 170.94K | Oct 30, 2024 |